Myofacial Pain and TMJ Disorders Botox Treatment with Oldness Affection
Keywords:
Myofascial Discomfort, Arthritis, Oldness, Botulinum Toxin, TMJ Problems.Abstract
TMJD is a disorder caused by masticatory myoarthropathy, which can be treated with botulinum toxin injections. This study aims to determine the effects of BTX-A injections on joint click, pain intensity, deviation on opening and maximum mouth opening. Male and female patients between the ages of 16 and 42 were included in the human sample, all of whom were experiencing myofacial discomfort, trismus, and TMJ noises due to temporomandibular joint dysfunction. Individuals receiving 100 U of botulinum toxin type A (BTX-A) injected at 100 mL per temporalis, lateral pterygoid and masseter muscle were enrolled in the trial. Each individual was randomly allocated to one of four groups.: 7 individuals, both male and female, aged 16-22, made up Group I. Patients aged 23-29 made up Group II, which also included 7 men. 7 individuals between the ages of 30 and 36 made up Group III. Group IV had 7 patients (aged 37-43) of both sexes experiencing myofacial discomfort due to temporomandibular joint dysfunction. This study evaluated damage to the teeth and gums from clenching and grinding, also known as bruxism or parafunction. Four key TMD symptoms were reported both before and after a BTX-A injection: pain level, maximum mouth opening, deviation on opening and joint click. Clinical effectiveness and safety were assessed ten days, 30 days, and 3 months following injection. Results showed that older patients in Group IV (older age) reported the highest mean and SD values for pain intensity, maximum mouth opening, joint click, and deviation on opening. Group III finished in second place, followed by Groups II and I. (younger age). Maximal mouth opening, joint click, and opening deviation all showed improvement in HS between the first (pre-treatment visit) and subsequent visits following BTX-A injection.
Downloads
References
Alexis K., Helios B. and Pierre C. et al. Assessing the
effectiveness of botulinum toxin injections into
masticatory muscles in the treatment of
temporomandibular disorders. Original Article.J Oral
Med Oral Surg 2018;24:107-111.
https://doi.org/10.1051/mbcb/2018001)
Niv M.( Christropher T. and Andrew B.
Temporomandibular Myofacial Pain Treated with
Botulinum Toxin Injection. Journal Toxins 2015,7,2791-
;doi:10.3390/toxins7082791.
www.mdpi.com/journal/toxins
Shilpa P.S., Kaul R., Sultana N. and Bhat S. Botulinum
toxin: The Midas touch. J. Nat. Sci. Biol. Med. 2014;5:8-
doi:10.4103/0976-9668.127274.
Khosla S. etal. Bisphosphonate-Associated Osteonecrosis
of the Jaw: Report of a TaskForce of the American
Society for Bone and Mineral Research. Journal of bone
and Mineral Research2OO7; 22:10.
Lagalla G., Millevolte M., Capecci M., Provinciali L.and
Ceravolo, M.G. Botulinum toxin type a for drooling in
Parkinson's disease: A double-blind, randomized,
placebo-controlled study.J. Mov. Disord 2006; 21: 704-
Hyun-Suk K., Pil-Young Y., and Young-Kyun K. A clinical
evaluation of botulinum toxin-A injections in the
temporomandibular disorder treatment.Maxillofac Plast
Reconstr Surg. 2016 Dec; 38(1): 5 .Published online 2016
Jan 28. doi: 10.1186/s40902-016-0051-7.
Deepak G., Soheyl S. Shambulingappa P., Ravinder S., and
Amit A. Correlation of Condylar Translation During
Maximal Mouth Opening with Presence of Signs of
Temporomandibular Joint Disorders in an
Asymptomatic Population of 18-25 Years Age Group of
Northern India.Open Dent J. 2018;12: 770-781. Published
online 2018 Sep 28.
doi:10.2174/1745017901814010770
Ravleen N., Deepa J., Shashikant S. Botulinum toxin in the
management of head and neck disorders.J. ORAL AND
MAXILLOFACIAL SURGERY 2017 April ;123: 4.
Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins:
from paralysis to recovery of functional neuromuscular
transmission. J Physiol Paris. 2002;96:105-13.
doi:10.1016/S0928-4257(01)00086-9
Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum
toxin type A induces direct analgesic effects in chronic
neuropathic pain. Ann Neurol. 2008;64:274-84. doi:
1002/ana.21427.
Dressier D, Adib Saberi F. Botulinum toxin: mechanisms
of action. Eur Neurol. 2005;53:3-9. doi:
O.1159/OOOO83259.
Molgorzoto P., Ewa F., Michal S., Katarzyna K., and
Mieszko W .The efficiency of botulinum toxin type A for
the treatment of masseter muscle pain in patients with
temporomandibular joint dysfunction and tension-type
headache.J Headache Pain 2017; 18(1): 38 .Published
online 2017 Mar 21. doi:10.1186/s10194-017-0744-z
Ronald S. P., Mark P. M., and Pamela J. Y.Communication
Breakdown: The Impact of Ageing on Synapse
Structure.Ageing Res Rev.J. HHS Author Manuscripts
Mar; 14: 31-42. PMC4094371. Published online 2014
Feb 2. doi: 10.1016/j.arr.2014.01.003
Peters A., Sethares C., Luebke J.Synapses are lost during
aging in the primate prefrontal cortex. J.Neuroscience
Apr 9;152(4):970-81.
Beramendi A., Peron S., Casanova G., Reggiani C„
Cantera R. Neuromuscular junction in abdominal
muscles of Drosophila melanogaster during adulthood
and aging.J Comp Neurol 2007 Apr 1; 501(4):498-508.
Patrick N. S., Donald T. K., and William E. G.Muscle
Changes in Aging Understanding Sarcopenia.J. Sports
Health 2014 Jan; 6(1): 36-40 .PMC3874224
.doi: 10.1177/1941738113502296.
Karsten K., and Martin E.Strength and muscle mass loss
with aging process. Age and strength loss. Muscles
Ligaments Tendons J. 2013 Oct-Dec; 3(4): 346-350.
PMC3940510
Jing L,Ying-Ying X., Qi-Lin Z., and Wei-Feng L.CIinical
StudyEfficacy and Safety of Botulinum Toxin Type A in
Treating Patients of Advanced Age with Idiopathic
Trigeminal Neuralgia.J. Hindawi Pain Research and
Management. Volume 2018, Article ID 7365148, 5 pages.
https://doi.org/10.1155/2018/7365148
H. Zhang, Y. Lian, Y. Ma et al., "Two doses of botulinum toxin type a for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial," Journal of Headache and Pain2014;15: 1,p. 65
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
